新型抗血小板药坎格瑞洛的国外研究现状

新型抗血小板药物坎格瑞洛是首个速效、静脉使用的抗血小板药物,可逆性地与P2Y12受体结合,发挥抗血小板作用,与传统的抗血小板药物氯吡格雷相比,其起效迅速、半衰期短,已广泛应用于需要进行冠脉介入治疗(PCI)的急性冠脉综合征(ACS)患者和心源性休克患者中。CHAMPION试验以患者死亡、心肌梗死和心肌缺血导致的血管重建作为观察终点,证实了坎格瑞洛的治疗作用。坎格瑞洛应用在原位心脏移植、发绀型先天性心脏病及肝素诱导血小板减少症(HIT)的治疗中,都展现了一定的优势。桥接疗法和过渡疗法使用坎格瑞洛与口服P2Y12受体抑制剂,在外科手术抗血小板和减少不良事件中发挥了重要作用。

Research status of cangrelor-a new antiplatelet drug abroad

Cangrelor,a new antiplatelet drug,is the first effective intravenous antiplatelet drug,which can be reversibly combined with P2 Y12 receptor to play an antiplatelet effect.Compared with the traditional antiplatelet drug clopidogrel,it takes effect more quickly with shorter half-life.It has been widely used in patients with acute coronary syndrome(ACS)and cardiogenic shock who need coronary intervention therapy(PCI).The CHAMPION test,which takes vascular reconstruction resulting from the death,myocardial infarction and myocardial ischemia as observation endpoint,confirms the therapeutic effect of cangrelor.Cangrelor shows some advantages in orthotopic heart transplantation and the treatment for cyanotic congenital heart disease and heparin-induced thrombocytopenia(HIT).Bridging therapy and transition therapy of cangrelor and oral P2 Y12 receptor inhibitors play an important role in surgical antiplatelet and reducing adverse events.